HC Wainwright Forecasts Strong Price Appreciation for DiaMedica Therapeutics (NASDAQ:DMAC) Stock

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) had its price target increased by HC Wainwright from $10.00 to $12.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price target would suggest a potential upside of 164.32% from the company's previous close.

DiaMedica Therapeutics Stock Up 8.6%

Shares of DMAC traded up $0.36 during mid-day trading on Friday, hitting $4.54. 831,248 shares of the company's stock were exchanged, compared to its average volume of 114,147. The firm has a fifty day moving average of $3.93 and a two-hundred day moving average of $4.68. DiaMedica Therapeutics has a twelve month low of $3.19 and a twelve month high of $6.82. The stock has a market cap of $194.68 million, a price-to-earnings ratio of -7.09 and a beta of 1.17.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, meeting analysts' consensus estimates of ($0.18). During the same period last year, the business earned ($0.14) earnings per share. On average, equities analysts predict that DiaMedica Therapeutics will post -0.59 earnings per share for the current year.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of institutional investors have recently made changes to their positions in DMAC. Paragon Associates & Paragon Associates II Joint Venture increased its position in shares of DiaMedica Therapeutics by 6.7% during the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 514,784 shares of the company's stock valued at $2,795,000 after acquiring an additional 32,170 shares during the last quarter. Susquehanna International Group LLP increased its position in shares of DiaMedica Therapeutics by 269.5% during the fourth quarter. Susquehanna International Group LLP now owns 374,845 shares of the company's stock valued at $2,035,000 after acquiring an additional 273,395 shares during the last quarter. Northern Trust Corp increased its position in shares of DiaMedica Therapeutics by 49.8% during the fourth quarter. Northern Trust Corp now owns 180,192 shares of the company's stock valued at $978,000 after acquiring an additional 59,902 shares during the last quarter. Royal Bank of Canada grew its holdings in DiaMedica Therapeutics by 46,879.1% during the first quarter. Royal Bank of Canada now owns 155,031 shares of the company's stock valued at $588,000 after purchasing an additional 154,701 shares during the period. Finally, LPL Financial LLC grew its holdings in DiaMedica Therapeutics by 8.2% during the fourth quarter. LPL Financial LLC now owns 152,000 shares of the company's stock valued at $825,000 after purchasing an additional 11,500 shares during the period. Institutional investors own 10.12% of the company's stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.